Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Multiple Sclerosis Subjects”

295 trials

Showing 20 of 295 results

Large-scale testing (Phase 3)Study completedNCT02525874
What this trial is testing

Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingMultiple Sclerosis
Biogen 218
Not applicableStudy completedNCT01435694
What this trial is testing

Robot-assisted Gait Training in Multiple Sclerosis Subjects

Who this might be right for
Multiple Sclerosis
University Hospital of Ferrara 60
Large-scale testing (Phase 3)Study completedNCT00488839
What this trial is testing

IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Impax Laboratories, LLC 173
Not applicableStudy completedNCT01909492
What this trial is testing

Measurement of Relaxin Peptide in Multiple Sclerosis (MS)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Providence Health & Services 30
Not applicableUnknownNCT03201692
What this trial is testing

Improving Dynamic Balance and Gait Adaptability Using Treadmill Training

Who this might be right for
Multiple SclerosisStrokeParkinson Disease
Fondazione Don Carlo Gnocchi ETS 48
Testing effectiveness (Phase 2)Ended earlyNCT03283826
What this trial is testing

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Who this might be right for
Primary Progressive Multiple SclerosisSecondary Progressive Multiple Sclerosis
Atara Biotherapeutics 134
Large-scale testing (Phase 3)Active Not RecruitingNCT06700343
What this trial is testing

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Who this might be right for
Relapsing-remitting Multiple Sclerosis (RRMS)
Amgen 152
Early research (Phase 1)Study completedNCT00837785
What this trial is testing

A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Biogen 48
Large-scale testing (Phase 3)Study completedNCT00139789
What this trial is testing

A Multicenter, Open-label Randomized Crossover Trial to Assess Subject Preference for Kemstro™ Compared to Conventional Baclofen Tablets in Subjects With Stable Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
UCB Pharma 60
Large-scale testing (Phase 3)Study completedNCT01844232
What this trial is testing

One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity

Who this might be right for
Multiple SclerosisSpasticity
RVL Pharmaceuticals, Inc. 150
Large-scale testing (Phase 3)WithdrawnNCT01868048
What this trial is testing

Phase 3, 28-week, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of Nabiximols as an add-on Therapy in Subjects With Spasticity Due to Multiple Sclerosis.

Who this might be right for
SpasticityMultiple Sclerosis
GW Research Ltd
Early research (Phase 1)Study completedNCT02442557
What this trial is testing

Safety and Dose-finding Study of DC-TAB in Healthy Subjects

Who this might be right for
Multiple Sclerosis
Delta Crystallon BV 76
Large-scale testing (Phase 3)Study completedNCT00681538
What this trial is testing

The Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)

Who this might be right for
SpasticityMultiple Sclerosis
Jazz Pharmaceuticals 572
Testing effectiveness (Phase 2)Study completedNCT00726648
What this trial is testing

CDP323 Biomarker Study

Who this might be right for
Relapsing Multiple Sclerosis
UCB Pharma 71
Post-approval studies (Phase 4)Study completedNCT02125604
What this trial is testing

Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 214
Large-scale testing (Phase 3)Study completedNCT00648908
What this trial is testing

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

Who this might be right for
Multiple Sclerosis
Acorda Therapeutics 269
Large-scale testing (Phase 3)Study completedNCT00869726
What this trial is testing

Patients With Secondary Progressive Multiple Sclerosis

Who this might be right for
Secondary Progressive Multiple Sclerosis
Eli Lilly and Company 596
Large-scale testing (Phase 3)Study completedNCT04121221
What this trial is testing

Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Mapi Pharma Ltd. 1,016
Post-approval studies (Phase 4)Study completedNCT00536120
What this trial is testing

The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis

Who this might be right for
Multiple Sclerosis
Biogen 60
Large-scale testing (Phase 3)Active Not RecruitingNCT04057898
What this trial is testing

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

Who this might be right for
Amyotrophic Lateral Sclerosis
MediciNova 234
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation